CB1 and CB2 receptors, plus the enzymes that make and destroy endocannabinoids, are expressed across the gastrointestinal tract, skin, liver, fat tissue and bone. The ECS is a whole-body regulatory network, which is why cannabinoid research now spans IBS, eczema, liver disease and osteoporosis.